Clinical Efficacy of Modified Lishui Qiangxin Decoction for Elderly Patients with Chronic Heart Failure and Its Effects on Ventricular Remodeling and Serum sTWEAK,hs-CRP,and IL-6 Levels
10.13359/j.cnki.gzxbtcm.2025.09.006
- VernacularTitle:利水强心汤加减治疗老年慢性心力衰竭的临床疗效及对心室重构和血清sTWEAK、hs-CRP、IL-6水平的影响
- Author:
Jianjing AN
1
;
Da ZHANG
;
Yue WANG
;
Lirui ZHANG
Author Information
1. 唐山中心医院,河北唐山 063000
- Keywords:
Lishui Qiangxin Decoction;
elderly;
chronic heart failure(CHF);
ventricular remodeling;
inflammatory factors;
sTWEAK;
high-sensitivity C-reactive protein(hs-CRP);
interleukin 6(IL-6);
quality of life
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(9):2126-2132
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of modified Lishui Qiangxin Decoction(composed of Astragali Radix,Arecae Pericarpium,Descurainiae Semen Lepidii Semen,Poria,Polyporus,Cinnamomi Ramulus,Salviae Miltiorrhizae Radix et Rhizoma,Asini Corii Colla,Aucklandiae Radix,etc.)for elderly patients with chronic heart failure(CHF),and to investigate its effects on ventricular remodeling and serum levels of soluble tumor necrosis factor-like weak inducer of apoptosis(sTWEAK),high-sensitivity C-reactive protein(hs-CRP),and interleukin 6(IL-6).Methods A total of 150 elderly CHF patients with yang-qi deficiency and water retention-blood stasis syndrome treated at Tangshan Central Hospital from December 2021 to December 2024 were enrolled.The patients were divided into trial(n=76)group and control(n=74)group.The control group received standard western treatment(vasodilation,diuresis,and cardiotonic therapy),while the trial group received additional modified Lishui Qiangxin Decoction,both groups were treated for 8 weeks.The changes in traditional Chinese medicine(TCM)syndrome scores,Minnesota Living with Heart Failure Questionnaire(MLHFQ)scores,ventricular remodeling parameters[left ventricular mass(LVM),early to late diastolic mitral inflow velocity ratio(E/A),left ventricular ejection fraction(LVEF)],serum sTWEAK,hs-CRP,and IL-6 levels were observed,and clinical efficacy was evaluated.Results(1)After 8 weeks of treatment,the overall response rate in the trial group was 97.37％(74/76),while that in the control group was 86.49％(64/74).The intergroup comparison(by chi-square test)showed that the efficacy of the trial group was significantly superior to that of the control group(P＜0.05).(2)After treatment,the TCM syndrome scores for dyspnea,edema,cold intolerance and cold limbs,and palpitations and shortness of breath were significantly lower in both groups compared to before treatment(P＜0.05).Additionally,the reduction in scores was significantly greater in the trial group than in the control group(P＜0.01).(3)After treatment,the LVM of both groups decreased compared to before treatment(P＜0.05),and the E/A and LVEF increased compared to before treatment(P＜0.05).The reduction in LVM and the increase in E/A and LVEF in the trial group were significantly greater than those in the control group(P＜0.01).(4)After treatment,the serum levels of sTWEAK,hs-CRP,and IL-6 in both groups decreased compared to before treatment(P＜0.05),and the reduction in the trial group was significantly greater than that in the control group(P＜0.01).(5)After treatment,the MLHFQ scores of emotional,physical,symptom dimensions and total score of the MLHFQ scale in both groups decreased compared to before treatment(P＜0.05),and the reduction in the trial group was significantly greater than that in the control group(P＜0.01).Conclusion Modified Lishui Qiangxin Decoction effectively alleviates symptoms,improves left ventricular function,reduces inflammatory markers of sTWEAK,hs-CRP and IL-6,and enhances quality of life in elderly CHF patients with yang-qi deficiency and water retention-blood stasis syndrome.
